Surgical site infections and dehiscence are among the most common post-operative wound complications, exerting significant burden on patients and healthcare systems. Risks of poor wound healing are exacerbated in aging populations, as well as patients with metabolic dysfunction, both of which are characterized by systemic decreases in cellular Nicotinamide Adenine Dinucleotide (NAD+). NAD+ depletion is thought to be at the center of the pathological crosstalk between senescence, inflammation, and mitochondrial/metabolic dysfunction, mechanisms which are heavily implicated in would healing and tissue repair. Even so, oral NAD+ has long been considered unachievable due to its size, polarity, and instability. The LathMize Green Platform Technology addresses these limitations, producing small labile molecules in a shelf-stable solid form (LNAD+) which, in aging adults from the recent RENEWAL-NAD+ randomized controlled trial, significantly increased intracellular NAD+ levels (53%) and upregulated SIRT1 protein expression (32%). Here we present the first reported clinical case using oral LNAD+ as an adjunct to accelerate healing of a complex surgical wound. his case demonstrates a potential correlation between oral LNAD+™ supplementation and rapid, high-quality resolution of complicated surgical wound dehiscence. Oral LNAD+™ presents a biologically plausible and non-invasive intervention to mitigate postoperative wound complications and enhance surgical recovery, warranting further investigation in prospective clinical trials.